Based on the success of the ISCR-CAS, the Beijing Institute for Stem Cell and Regenerative Medicine (BISCRM) was founded in 2020 as a joint strategic innovation initiative of CAS and the Beijing Municipal Government. BISCRM conducts original research targeting unmet national needs, while pushing the frontiers in stem cell and regenerative medicine. BISCRM integrates wide-ranging competencies and resources to establish world-leading platforms and attract global talent and research teams. With strong support from both CAS and the Beijing local government, BISCRM PIs are poised to achieve major scientific breakthroughs in various exciting fields.